Literature DB >> 22074624

Human embryonic stem cell-derived mesenchymal stromal cells.

Peiman Hematti1.   

Abstract

Mesenchymal stromal cells (MSCs) originally isolated from marrow have multipotent differentiation potential and favorable immunomodulatory and anti-inflammatory properties that make them very attractive for regenerative cellular therapy. Cells with similar phenotypic characteristics have now been derived from almost all fetal, neonatal, and adult tissues; furthermore, more recently similar cells have also been generated from human embryonic stem cells (ESCs). Generation of MSCs from human ESCs provides an opportunity to study the developmental biology of human mesenchymal lineage generation in vitro. Generation of bone and cartilage from human ESC-derived MSCs and their functional characterization, both in vitro and in vivo, is also an active area of investigation as ESCs could provide an unlimited source of MSCs for potential repair of bone and cartilage defects. MSCs from adult sources are being investigated in numerous Phase I-III clinical trials for a wide variety of indications, mainly based on their immunomodulatory properties. Our group and others have shown MSCs derived from human ESCs possess immunomodulatory properties similar to marrow-derived MSCs. Immunomodulatory properties of ESC-derived MSCs could prove to be highly valuable for their potential clinical applications in the future as derivatives of human ESCs have already entered clinical arena in the context of Phase I clinical trials.
© 2011 American Association of Blood Banks.

Entities:  

Mesh:

Year:  2011        PMID: 22074624      PMCID: PMC3261503          DOI: 10.1111/j.1537-2995.2011.03376.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  77 in total

1.  Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa.

Authors:  Massimo Dominici; Paolo Paolucci; Pierfranco Conte; Edwin M Horwitz
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

2.  Brief report--human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes.

Authors:  B Linju Yen; Chan Jung Chang; Ko-Jiunn Liu; Yao Chang Chen; Hsin-I Hu; Chi-Huey Bai; Men-Luh Yen
Journal:  Stem Cells       Date:  2009-02       Impact factor: 6.277

3.  Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.

Authors:  Jaehyup Kim; Peiman Hematti
Journal:  Exp Hematol       Date:  2009-09-20       Impact factor: 3.084

4.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.

Authors:  Ryang Hwa Lee; Andrey A Pulin; Min Jeong Seo; Daniel J Kota; Joni Ylostalo; Benjamin L Larson; Laura Semprun-Prieto; Patrice Delafontaine; Darwin J Prockop
Journal:  Cell Stem Cell       Date:  2009-07-02       Impact factor: 24.633

5.  Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.

Authors:  Krisztián Németh; Asada Leelahavanichkul; Peter S T Yuen; Balázs Mayer; Alissa Parmelee; Kent Doi; Pamela G Robey; Kantima Leelahavanichkul; Beverly H Koller; Jared M Brown; Xuzhen Hu; Ivett Jelinek; Robert A Star; Eva Mezey
Journal:  Nat Med       Date:  2008-11-21       Impact factor: 53.440

6.  Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1.

Authors:  Gregory J Block; Shinya Ohkouchi; France Fung; Joshua Frenkel; Carl Gregory; Radhika Pochampally; Gabriel DiMattia; Deborah E Sullivan; Darwin J Prockop
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

Review 7.  Cell therapy approaches for lung diseases: current status.

Authors:  Viranuj Sueblinvong; Daniel J Weiss
Journal:  Curr Opin Pharmacol       Date:  2009-04-06       Impact factor: 5.547

8.  Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.

Authors:  H Deda; M C Inci; A E Kürekçi; A Sav; K Kayihan; E Ozgün; G E Ustünsoy; S Kocabay
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

Review 9.  Role of mesenchymal stromal cells in solid organ transplantation.

Authors:  Peiman Hematti
Journal:  Transplant Rev (Orlando)       Date:  2008-07-24       Impact factor: 3.943

Review 10.  Mesenchymal stem cells in hematopoietic stem cell transplantation.

Authors:  Minoo Battiwalla; Peiman Hematti
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more
  6 in total

1.  A Systems-level Characterization of the Differentiation of Human Embryonic Stem Cells into Mesenchymal Stem Cells.

Authors:  Anja M Billing; Shaima S Dib; Aditya M Bhagwat; Israel T da Silva; Rodrigo D Drummond; Shahina Hayat; Rasha Al-Mismar; Hisham Ben-Hamidane; Neha Goswami; Kasper Engholm-Keller; Martin R Larsen; Karsten Suhre; Arash Rafii; Johannes Graumann
Journal:  Mol Cell Proteomics       Date:  2019-07-22       Impact factor: 5.911

Review 2.  Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.

Authors:  S D Sackett; M E Brown; D M Tremmel; T Ellis; W J Burlingham; J S Odorico
Journal:  Transplant Rev (Orlando)       Date:  2016-02-10       Impact factor: 3.943

3.  A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement.

Authors:  Carlos Luzzani; Gabriel Neiman; Ximena Garate; María Questa; Claudia Solari; Darío Fernandez Espinosa; Marcela García; Ana Lía Errecalde; Alejandra Guberman; María Elida Scassa; Gustavo Emilio Sevlever; Leonardo Romorini; Santiago Gabriel Miriuka
Journal:  Stem Cell Res Ther       Date:  2015-01-12       Impact factor: 6.832

4.  Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers.

Authors:  Anja M Billing; Hisham Ben Hamidane; Shaima S Dib; Richard J Cotton; Aditya M Bhagwat; Pankaj Kumar; Shahina Hayat; Noha A Yousri; Neha Goswami; Karsten Suhre; Arash Rafii; Johannes Graumann
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

Review 5.  Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease.

Authors:  Fei Mao; Qiang Tu; Li Wang; Fuliang Chu; Xia Li; Haiyan S Li; Wenrong Xu
Journal:  Oncotarget       Date:  2017-06-06

6.  Hypoxia Pre-Conditioned Embryonic Mesenchymal Stem Cell Secretome Reduces IL-10 Production by Peripheral Blood Mononuclear Cells.

Authors:  Majid Lotfinia; Shirin Lak; Nastaran Mohammadi Ghahhari; Behrooz Johari; Faezeh Maghsood; Sara Parsania; Bahareh Sadegh Tabrizi; Mehdi Kadivar
Journal:  Iran Biomed J       Date:  2016-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.